is hims still selling semaglutide Novo Nordisk drops its & Hers patent lawsuit as Wegovy and Ozempic head to the Hims platform Hims & Hers abandons copycat

Alkhatib, Jordan University of Science and Technology, Jordan Jiaqin Wu, Chongqing University, China Updates Copyright 2026 Sun and Lv

Here is how the leading options stack up: | Feature | Semaglutide | Tirzepatide | Retatrutide | Liraglutide | |---------|-------------|-------------|-------------|-------------| | **Mechanism** | GLP-1 | GLP-1 + GIP | GLP-1 + GIP + Glucagon | GLP-1 | | **Dosing** | Weekly | Weekly | Weekly | Daily | | **Max Dose** | 2.4mg | 15mg (FDA) | 12mg (trial) | 3mg | | **Avg Weight Loss** | 15-17% | 20-22% | 22-24% | 8-10% | | **FDA Approved** | Yes | Yes | Phase 3 | Yes | | **Oral Option** | Yes (Rybelsus) | No | No | No | ## Semaglutide (Ozempic / Wegovy): The Proven Standard Semaglutide was the medication that transformed obesity treatment from a niche specialty into mainstream medicine

For consumer health companies, the opportunity here is clear

[,] It is known that the skin microbiome may interfere with the immune system via interaction with keratinocytes

Think of it as your cells' internal janitor, security guard, and repairman all rolled into one